Intradermal Influenza Vaccine Study in Elders

• ClinicalTrials.gov Identifier: NCT00504231
• Recruitment Status: Completed
• First Posted: July 19, 2007
• Results First Posted: July 13, 2012
• Last Update Posted: July 13, 2012
• Sponsor: PATH
• Collaborators: VA Puget Sound Health Care System; Seattle Institute for Biomedical and Clinical Research
• Information provided by (Responsible Party): PATH

Study Description

Brief Summary:

This randomized trial compared the immunogenicity of 60% dose intradermal (ID) influenza vaccination to standard intramuscular (IM) vaccination of full-dose or 60% dose vaccine. Pre- and postvaccination measurements in the hemagglutination inhibition antibody (HAI) titer were compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM vaccine.

Condition or disease	Intervention/treatment	Phase
Influenza	Biological: Fluzone Influenza Vaccine (2007-2008)	Phase 2

Detailed Description:

This study was an open-label randomized trial consisting of community-dwelling adults 65 years and older living in Puget Sound area in Washington State. Subjects were enrolled and randomly assigned to receive licensed, 2007-2008 Northern Hemisphere TIV vaccine (Fluzone, lot U2440AA; Sanofi Pasteur) containing concentrations of hemagglutinin of each of A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004 (B): 15 ug/0.5 mL by the IM route, 9 ug/0.3 mL by the ID or IM route, or 4.5 ug/0.15 mL given twice by ID route to the nondominant arm. A block randomization scheme (1:1:1:1), stratified by sex, was used. For IM vaccination, 0.3 mL or 0.5 mL of vaccine was removed from a multidose (5 mL) vial through a 25-gauge, 1-inch detachable needle (Becton Dickinson) and was injected into the deltoid muscle at a 90 degree angle to the skin. For ID vaccination, 0.3 mL or 0.15 mL was drawn by a TB syringe through a 25-gauge, 5/8-inch needle (Terumo Medical). The needle was inserted at a 15 degree angle to the skin overlying the deltoid of the arm. The vaccine was slowly injected until all material was expelled and induration appeared. Subjects randomized to the 0.15-mL group received 2 side-by-side ID injections 3 cm apart. Participants returned at 4 weeks to determine postvaccination antibody titers. At this follow-up visit, those assigned to reduced dose IM or ID influenza vaccinations then received full-dose IM influenza vaccination. These participants returned in another 4 weeks to repeat HAI titers. A nonrandomized subset of subjects (based on availability and willingness to participate) returned at 14 days after initial vaccination for T cell assays in an exploratory substudy to examine cellular immune response.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 257 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Intradermal vs. Intramuscular Delivery of Influenza Vaccine in Immunocompetent Elders
• Study Start Date: September 2007
• Actual Primary Completion Date: January 2008
• Actual Study Completion Date: January 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: 0.3 mL Influenza Vaccine ID; 60% dose - 0.3 mL delivered intradermally with needle and syringe	Biological: Fluzone Influenza Vaccine (2007-2008); Manufactured by Sanofi Pasteur; Other Name: Fluzone
Experimental: 0.15 mL twice Influenza Vaccine ID; 60% dose - 0.15 mL delivered twice intradermally with needle and syringe	Biological: Fluzone Influenza Vaccine (2007-2008); Manufactured by Sanofi Pasteur; Other Name: Fluzone
Active Comparator: 0.5 mL Influenza Vaccine by IM; 100% dose - 0.5mL delivered intramuscularly with needle and syringe	Biological: Fluzone Influenza Vaccine (2007-2008); Manufactured by Sanofi Pasteur; Other Name: Fluzone
Experimental: 0.3 mL Influenza Vaccine IM; 60% dose - 0.3 mL delivered intramuscularly with needle and syringe	Biological: Fluzone Influenza Vaccine (2007-2008); Manufactured by Sanofi Pasteur; Other Name: Fluzone

Outcome Measures

Primary Outcome Measures :

1. Seroprotection Pre- and Post- Vaccination [ Time Frame: 1 month ]
   Seroprotection before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) Intramuscular (IM) or Reduced-Dose (9 mg) Intradermal (ID) Injections for A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)

Secondary Outcome Measures :

1. Geometric Mean Titer (GMT) Pre- and Post- Vaccination [ Time Frame: 1 month ]
   GMT before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) IM or Reduced-Dose (9 mg) ID Injections. A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)
2. Assessment of Reactogenicity [ Time Frame: 1 week ]
   Maximum solicited systemic and local signs and symptoms during the week after initial vaccination, by Dose and Randomization Assignment

Eligibility Criteria

• Ages Eligible for Study: 65 Years and older (Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Ambulatory, medically stable persons 65 years of age or older
• Able to read and understand informed consent
• Available during the trial period and for follow-up
• Able to understand and comply with planned study procedures
• Able to be contacted by telephone for follow-up of adverse events

Exclusion Criteria:

• Known allergy to eggs or other components of vaccine (i.e., thimerosal)
• History of Guillain-Barré Syndrome (GBS)
• Has a confirmed or suspected immunodeficient or immunosuppressive condition (including congenital or acquired immunosuppressive therapy, and human immunodeficiency virus [HIV])
• End-stage renal disease requiring hemodialysis
• Active neoplastic disease or history of any hematologic malignancy (except localized skin or prostate cancer that is stable in the absence of therapy)
• Acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses (including but not limited to the following: known chronic liver disease, significant renal disease, oxygen-dependent chronic lung disease, New York Heart Association Functional Class III or IV, unstable or progressive neurologic disorder, insulin controlled diabetes mellitus)
• Use of experimental vaccines within the month prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products during the duration of the study.
• Receipt of immunoglobulin or other blood product within 3 months prior to enrollment
• Receipt of other licensed vaccines within the preceding 4 weeks
• History of a severe reaction following influenza vaccination
• Current or planned participation in a research study of an investigational drug. Participation in research studies that involve use of licensed drugs, for either approved or investigational indications, will be permitted with the approval of the PI, as will participation in research studies that do not involve vaccines or medications.
• Current use or previous chronic administration, defined as >14 days during the previous six months, of immunosuppressants or other immune-modifying drugs. (For oral or injected corticosteroids, the immune-modifying dose is defined as prednisone or its equivalent >10 mg/day or >800mcg per day of inhaled beclomethasone dipropionate or equivalent ). Topical steroids are allowed.
• Use of cytotoxic therapy in the previous 2 years.
• Plans to receive cytotoxic therapy during the study period.
• Concurrent moderate to severe illness. Need to defer vaccination until recovery. (Vaccination is not contraindicated in subjects with mild illnesses or with low-grade fever).

Contacts and Locations

Sponsors and Collaborators

PATH

VA Puget Sound Health Care System

Seattle Institute for Biomedical and Clinical Research

Investigators

• Principal Investigator: Ru-Chien Chi, MD; VAPSHCS
• Principal Investigator: Kathy Neuzil, MD; PATH

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis. 2010 May 15;50(10):1331-8. doi: 10.1086/652144.

• Responsible Party: PATH
• ClinicalTrials.gov Identifier: NCT00504231
• Other Study ID Numbers: ID/RD01
• First Posted: July 19, 2007
• Results First Posted: July 13, 2012
• Last Update Posted: July 13, 2012
• Last Verified: July 2011

Keywords provided by PATH:

influenza; prevention; intradermal; vaccine; delivery; elderly

Additional relevant MeSH terms:

Influenza, Human; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Infections; Respiratory Tract Diseases